The FDA's Overton era, and dispatches from Sh...

International researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for the future of American medical research? We discuss that, plus the latest news in the life sciences, on this we ...  Show more

On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did they fail? And what does this mean for the development of new heart medicines moving forward? C ...  Show more

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ...  Show more

Pharma stocks breaking out, as President Trump inks a drug pricing deal. What it means for the group, and how the broader health care sector is breathing a sigh of relief. Plus Elon Musk and some bingeing backlash. Why the billionaire is calling for customers to cancel their s ...

Barron's senior managing editor Lauren R. Rublin and healthcare industry reporter Josh Nathan-Kazis discuss the outlook for healthcare stocks, and the latest news on Covid-19 treatments and vaccines. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information ab ...  Show more

Do you have a real relationship or just a non-binding letter of intent? (00:21) Nick Sciple and Mary Long discuss: - The S&P’s turnaround and inflation’s slow month-over-month decline. - A stock pop from a nuclear reactor company that doesn’t have a working nuclear reactor. - Pri ...  Show more